CY1108262T1 - Φαρμακευτικες συνθεσεις που περιεχουν φθοριωμενα ή υπερφθοριωμενα καρβοξυλικα οξεα - Google Patents
Φαρμακευτικες συνθεσεις που περιεχουν φθοριωμενα ή υπερφθοριωμενα καρβοξυλικα οξεαInfo
- Publication number
- CY1108262T1 CY1108262T1 CY20081100865T CY081100865T CY1108262T1 CY 1108262 T1 CY1108262 T1 CY 1108262T1 CY 20081100865 T CY20081100865 T CY 20081100865T CY 081100865 T CY081100865 T CY 081100865T CY 1108262 T1 CY1108262 T1 CY 1108262T1
- Authority
- CY
- Cyprus
- Prior art keywords
- overflued
- fluorified
- pharmaceutical compositions
- carboxylic acids
- compositions containing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
Abstract
Τα μόρια του τύπου (I) είναι χρήσιμα στη θεραπεία του διαβήτη, της παχυσαρκίας, της υπερχοληστερολαιμίας, της υπερλιπιδαιμίας, του καρκίνου, της φλεγμονής ή άλλων παθήσεων στις οποίες η ρύθμιση της λιπιδικής κατάστασης ή της κατάστασης των εικοσανοειδών ενδέχεται να είναι επιθυμητή. Τύπος (I): Ζ1-Χ-Ζ2 όπου α) το Ζ1 αντιπροσωπεύει CO2H ή ένα παράγωγο του, β) το Ζ2 αντιπροσωπεύει F, Η, -CO2H ή ένα παράγωγο του και γ) το Χ αντιπροσωπεύει φθοριωμένο αλκυλένιο, ή ένα διάλυμα του, για παράδειγμα ένα υπερφθοριωμένο λιπαρό οξύ ή παράγωγο του.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0103809.0A GB0103809D0 (en) | 2001-02-16 | 2001-02-16 | Methods |
| EP02712094A EP1359906B1 (en) | 2001-02-16 | 2002-02-18 | Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108262T1 true CY1108262T1 (el) | 2014-02-12 |
Family
ID=9908862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100865T CY1108262T1 (el) | 2001-02-16 | 2008-08-13 | Φαρμακευτικες συνθεσεις που περιεχουν φθοριωμενα ή υπερφθοριωμενα καρβοξυλικα οξεα |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8487003B2 (el) |
| EP (3) | EP2260842A2 (el) |
| JP (2) | JP4652665B2 (el) |
| AT (1) | ATE395054T1 (el) |
| AU (3) | AU2002232001B2 (el) |
| CA (2) | CA2737095A1 (el) |
| CY (1) | CY1108262T1 (el) |
| DE (1) | DE60226575D1 (el) |
| DK (1) | DK1359906T3 (el) |
| ES (1) | ES2309153T3 (el) |
| GB (2) | GB0103809D0 (el) |
| PT (1) | PT1359906E (el) |
| WO (1) | WO2002066028A2 (el) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0220045D0 (en) * | 2002-08-29 | 2002-10-09 | Cxr Biosciences Ltd Sc 211745 | Methods |
| WO2010076333A1 (en) * | 2009-01-02 | 2010-07-08 | Fournier Laboratories Ireland Limited | Novel use of fibrates |
| EP2459182B1 (en) * | 2009-07-30 | 2017-09-06 | University of Zürich | Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
| GB201002861D0 (en) * | 2010-02-19 | 2010-04-07 | Cxr Biosciences Ltd | Compositions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2567011A (en) | 1949-01-10 | 1951-09-04 | Minnesota Mining & Mfg | Fluorocarbon acids and derivatives |
| US4624851A (en) | 1983-04-22 | 1986-11-25 | Elena Avram | Treatment of symptoms of neoplastic diseases |
| DE4040619A1 (de) * | 1990-12-19 | 1992-06-25 | Boehringer Mannheim Gmbh | Neue aliphatische amide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| US5621144A (en) | 1991-11-29 | 1997-04-15 | Isis Innovation Limited | Fluorinated compounds as oxygen transport agents |
| GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| US6013795A (en) | 1996-11-04 | 2000-01-11 | 3M Innovative Properties Company | Alpha-branched fluoroalkylcarbonyl fluorides and their derivatives |
| US6015838A (en) | 1996-11-04 | 2000-01-18 | 3M Innovative Properties Company | Aqueous film-forming foam compositions |
| EP1098641B1 (en) | 1998-07-27 | 2016-04-27 | St. Jude Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| GB9917405D0 (en) | 1999-07-23 | 1999-09-22 | Univ Dundee | Methods of treatment and drug screening methods |
| GB0220045D0 (en) | 2002-08-29 | 2002-10-09 | Cxr Biosciences Ltd Sc 211745 | Methods |
| US6875060B2 (en) * | 2002-10-21 | 2005-04-05 | Adc Telecommunications, Inc. | High density patching system |
-
2001
- 2001-02-16 GB GBGB0103809.0A patent/GB0103809D0/en not_active Ceased
-
2002
- 2002-02-18 JP JP2002565586A patent/JP4652665B2/ja not_active Expired - Fee Related
- 2002-02-18 PT PT02712094T patent/PT1359906E/pt unknown
- 2002-02-18 CA CA2737095A patent/CA2737095A1/en not_active Abandoned
- 2002-02-18 US US10/468,331 patent/US8487003B2/en not_active Expired - Fee Related
- 2002-02-18 WO PCT/GB2002/000726 patent/WO2002066028A2/en active IP Right Grant
- 2002-02-18 DK DK02712094T patent/DK1359906T3/da active
- 2002-02-18 AT AT02712094T patent/ATE395054T1/de active
- 2002-02-18 EP EP10075491A patent/EP2260842A2/en not_active Withdrawn
- 2002-02-18 AU AU2002232001A patent/AU2002232001B2/en not_active Ceased
- 2002-02-18 GB GB0203716A patent/GB2383535B/en not_active Expired - Fee Related
- 2002-02-18 DE DE60226575T patent/DE60226575D1/de not_active Expired - Lifetime
- 2002-02-18 CA CA2438085A patent/CA2438085C/en not_active Expired - Fee Related
- 2002-02-18 EP EP06076555A patent/EP1745779A3/en not_active Withdrawn
- 2002-02-18 EP EP02712094A patent/EP1359906B1/en not_active Expired - Lifetime
- 2002-02-18 ES ES02712094T patent/ES2309153T3/es not_active Expired - Lifetime
-
2006
- 2006-09-29 AU AU2006222766A patent/AU2006222766B2/en not_active Ceased
-
2008
- 2008-08-13 CY CY20081100865T patent/CY1108262T1/el unknown
-
2009
- 2009-03-02 JP JP2009048194A patent/JP2009132726A/ja active Pending
- 2009-11-05 AU AU2009233689A patent/AU2009233689A1/en not_active Abandoned
-
2011
- 2011-03-24 US US13/071,240 patent/US20120029079A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1359906B1 (en) | 2008-05-14 |
| AU2002232001B2 (en) | 2006-06-29 |
| US20120029079A1 (en) | 2012-02-02 |
| DE60226575D1 (de) | 2008-06-26 |
| CA2438085A1 (en) | 2002-08-29 |
| AU2006222766B2 (en) | 2009-08-06 |
| AU2006222766A1 (en) | 2006-11-02 |
| DK1359906T3 (da) | 2008-09-15 |
| EP1359906A2 (en) | 2003-11-12 |
| GB0203716D0 (en) | 2002-04-03 |
| US8487003B2 (en) | 2013-07-16 |
| CA2737095A1 (en) | 2002-08-29 |
| GB2383535B (en) | 2005-09-21 |
| ATE395054T1 (de) | 2008-05-15 |
| EP1745779A2 (en) | 2007-01-24 |
| PT1359906E (pt) | 2008-08-26 |
| CA2438085C (en) | 2011-05-03 |
| JP2009132726A (ja) | 2009-06-18 |
| GB2383535A (en) | 2003-07-02 |
| GB0103809D0 (en) | 2001-04-04 |
| JP4652665B2 (ja) | 2011-03-16 |
| ES2309153T3 (es) | 2008-12-16 |
| WO2002066028A3 (en) | 2002-11-14 |
| EP2260842A2 (en) | 2010-12-15 |
| US20050175639A1 (en) | 2005-08-11 |
| EP1745779A3 (en) | 2011-05-04 |
| AU2009233689A1 (en) | 2009-11-26 |
| JP2004531482A (ja) | 2004-10-14 |
| WO2002066028A2 (en) | 2002-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108262T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν φθοριωμενα ή υπερφθοριωμενα καρβοξυλικα οξεα | |
| FR2799759B1 (fr) | Composition, notamment cosmetique, comprenant une sapogenine | |
| DE60207234D1 (de) | Verfahren zur herstellung einer gereinigten shilajit-zusammensetzung aus nativem shilajit | |
| BRPI9909282B8 (pt) | compostos de Éter aminociclohexÍlicos e usos dos mesmos. | |
| EP1690536A3 (de) | Verwendung von r-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxy-methyl-Phenylisobuttersäureester Hydrogenfumarat zur Behandlung von Harndrang-Inkontinenz und anderen spasmogenen Leiden | |
| DK1135998T3 (da) | Anvendelse af syntetiske triglycerider på basis af konjugeret linolsyre som antioxidant i levnedsmidler | |
| FI956341A (fi) | Metyylifosfonihappoesteri, menetelmä sen valmistamiseksi ja sen käyttö | |
| ATE241592T1 (de) | Benzoesäureesterderivate, diese enthaltende zusammenstellungen und deren anwendung | |
| BR0215027A (pt) | Derivados de 6-aminomorfinano, processo de preparação para o mesmo e sua aplicação | |
| ATE302746T1 (de) | Amorphe salpetersäureester und deren pharmazeutische zusammensetzungen | |
| ATE294593T1 (de) | Inclusion-komplex von beta-cyclodextrin mit diclofenac | |
| EA200200875A1 (ru) | Пролекарства производных имидазопиридина | |
| FR2826961B1 (fr) | Procede de preparation d'anhydride (meth) acrylique | |
| MY128392A (en) | 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(2-FURANYLCARBOXYL)OXY]-11ß-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT | |
| BR0208275A (pt) | Composições farmacêuticas para tratamento de arteriosclerose | |
| BR0208999A (pt) | Processo para a preparação de ácido de cefpodoxima | |
| ATE360027T1 (de) | 11beta-langkettig-substituierte estratriene, verfahren zur herstellung, pharmazeutische präparate, die diese 11beta-langkettig- substituierten estratriene enthalten, sowie deren verwendung zur herstellung von arzneimitteln | |
| AU2002342498A1 (en) | Organic compounds | |
| ES2097296T3 (es) | Composicion acida desinfectante con caracteristicas detergentes y desincrustantes y procedimiento para su fabricacion. | |
| ATE302752T1 (de) | Benzoesäureester und flüssigkristallmedium | |
| ATE206065T1 (de) | Oberflächenaktive polyethylenoxyfettsäureester und deren verwendung | |
| DE50202087D1 (de) | Verfahren zur Herstellung von Hydroxybenzoesäurebenzylestern | |
| ATE245621T1 (de) | (+)- und (-)-2-cyclododecylpropanol und (+)- und (-)-2-cyclododecylpropionsäure sowie deren herstellung und verwendung | |
| DE50008094D1 (de) | Tetramsäure-Derivate zur Verwendung in Medizin und Lebensmitteltechnologie | |
| DE60123058D1 (de) | Neue cytotoxische verbindungen und deren verwendung |